View Profile

Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors Review type Summary Keywords File filename File mime type
1. 2013 A feasibility study of outpatient chemotherapy with S-1 + cisplatin in patients with advanced gastric cancer Gastric Cancer. Epub ahead of print
2. 2013 Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis. Int J Cancer. Epub ahead of print
3. 2013 Multicenter Feasibility Study of Combination Therapy with Fluorouracil, Leucovorin and Paclitaxel (FLTAX) for Peritoneal Disseminated Gastric Cancer with Massive Ascites or Inadequate Oral Intake Japanese Journal of Clinical Oncology Epub ahead of print.
4. 2012 Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer Cancer Chemother Pharmacol. 69: 439-446, 2012
5. 2012 First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer Gastric Cancer. 15: 21-26, 2012
6. 2012 Nucleostemin and TWIST as predictive markers for recurrence after neoadjuvant chemotherapy for esophageal carcinoma Cancer Sci. 103: 233-238, 2012
7. 2011 Phase II study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel as first-line therapy for advanced gastric cancer Oncology. 81: 291-297, 2011
8. 2011 Genetic variation and haplotype structures of the glutathione S-transferase genes, GSTA1 and GSTA2, in Japanese colorectal cancer patients. Drug Metab Pharmacokinet. 26: 646-658, 2011
9. 2011 Characteristics and outcome of patients with advanced gastric cancer who declined to participate in a randomized clinical chemotherapy trial J Oncol Pract. 7: 148-153, 2011
10. 2011 Management of adjuvant S-1 therapy after curative resection of gastric cancer: dose reduction and treatment schedule modification Gastric Cancer. 14: 28-34, 2011
11. 2011 Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma Gastric Cancer. 14: 161-165, 2011
12. 2011 Systemic chemotherapy for peritoneal disseminated gastric cancer with inadequate oral intake: a retrospective study. Int J Clin Oncol. 16: 57-62, 2011
13. 2010 Adipocytokines as New Promising Markers of Colorectal Tumors: Adiponectin for Colorectal Adenoma, and Resistin and Visfatin for Colorectal Cancer Cancer Science 101 : 1286-1291, 2010
14. 2010 Genetic polymorphisms of FCGRT encoding FcRn in a Japanese population and their functional analysis. Drug Metab Pharmacokinet 25: 578-587, 2010
15. 2010 Sequential chemotherapy with methotrexate and 5-fluorouracil for chemotherapy-naïve advanced gastric cancer with disseminated intravascular coagulation at initial diagnosis J Cancer Res Clin Oncol 136: 243-248, 2010
16. 2010 Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors Clin Cancer Res 16: 5058-5066, 2010
17. 2010 Plasma concentration of VCAM-1 and PAI-1: A predictive biomarker for post-operative recurrence in colorectal cancer Cancer Science 101: 1886-1890, 2010
18. 2010 Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer J Cancer Res Clin Oncol 136: 1059-1064, 2010
19. 2009 Effects of bavacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy Cancer Chemother Pharmacol 65: 467-471, 2009
20. 2009 A Phase I Trial of 5-fluorouracil with Cisplatin and Concurrent Standard-dose Radiotherapy in Japanese Patients with Stage II/III Esophageal Cancer. Japanese Journal of Clinical Oncology 39 (1): 37-42, 2009
21. 2009 Adipocytokine levels in gastric cancer patients – Resistin and visfatin as biomarkers of gastric cancer and its stage progression, and adiponectin as a biomarker of early stage J Gastroenterology 44: 685-690, 2009
22. 2009 Palliative radiation therapy for hemorrhage of unresectable gastric cancer: a single institute experience J Cancer Res Clin Oncol 135: 1117-1123, 2009
23. 2009 Lymoh node staging in esophageal squamous cell carcinoma: A comparative study of endoscopic ultrasonography versus computed tomography J Gastroen Hepatol 24: 1687-1691, 2009
24. 2009 Adipocytokines and squamous cell carcinoma of the esophagus J Cancer Res Clin Oncol 136: 261-266, 2009.
25. 2009 Genetic polymorphisms of copper- and platinum drug-efflux transporters ATP7A and ATP7B in Japanese cancer patients Drug Metab Pharmacokinet 24: 565-574, 2009
26. 2009 Standard First-Line Chemotherapy for Metastatic Gastric Cancer in Japan Has Met the Global Standard: Evidence From Recent Phase III Trials Gastrointest Cancer Res. 3: 239-244, 2009
27. 2008 Clinical Significance of Insulin-Like Growth Factor Receptor in Patients with Advanced Gastric Cancer Oncology 74: 76-83, 2008
28. 2008 Combination chemotherapy with cisplatin and irinotecan in patients with adenocarcinoma of the small intestine Gastric Cancer 11: 201-205, 2008
29. 2008 Antitumor Effect of SN-38-Releasing Polymeric Micelles, NK012, on Spontaneous Peritoneal Metastasis from Orthotopic Gastric Cancer in Mice Compared with Irinotecan Cancer Research 68 (22): 9318-9322, 2008
30. 2008 A Phase I Study of Bolus 5-fluorouracil and Leucovorin Combined with Weekly Paclitaxel (FLTAX) as First-line Therapy for Advanced Gastric Cancer Japanese Journal of Clinical Oncology 38 (8): 540-546, 2008
31. 2008 Chemosensitivity of patients with recurrent esophageal cancer receiving perioperative chemotherapy Diseases of the Esophagus 21 (7): 607-11, 2008
32. 2008 Combination of O6-methylguanine-DNA methyltransferase and thymidylate synthase for the prediction of fluoropyrimidine efficacy European Journal of Cancer 44: 400-407, 2008
33. 2008 Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil International Journal of Cancer 122: 2148-2153, 2008
34. 2008 Impact of excision repair cross-complementing gene I (ERCC1), dihydropyrimidine degydrogenese, and epidermal growth factor receptor on the outocomes of patients with advanced gastric cancer British Journal of Cancer 98: 832-839, 2008
35. 2007 Distribution and significance of the esophageal and gastric cardiac mucosae: a study of 131 operation specimens Histopathology 51: 515-519, 2007
36. 2006 Metachronous gastric cancers after endoscopic resecton: how effective is annual endoscopic surveillance? Gastric Cancer 9(2): 93-98, 2006
37. 2006 Histopathological criteria for additional treatment after endoscopic mucosal resection for esophageal cancer: Analysis of 464 surgically resected cases Modern Pathology 19: 475-480, 2006
38. 2003 Is Endoscopic One-piece Mucosal Resection Essential for Early Gastric Cancer ? Digestive Endoscopy 15:113-116, 2003
39. 2001 Hypoglycemia Associated with the Production of Insulin-like Growth Factor â…¡ in Adenocortical Carcinoma Internal Medicine 40:759-763,2001
40. Colorectal cancer (CRC) is one of the most daunting diseases due to its increasing worldwide prevalence, which requires imperative development of minimally or non-invasive screening tests. Pubmed Colorectal cancer (CRC) is one of the most daunting diseases due to its increasing worldwide prevalence, which requires imperative development of minimally or non-invasive screening tests. Urinary polyamines have been reported as potential markers to detect CRC, and an accurate pattern recognition to differentiate CRC with early stage cases from healthy controls are needed. Here, we utilized liquid chromatography triple quadrupole mass spectrometry to profile seven kinds of polyamines, such as spermine and spermidine with their acetylated forms. Urinary samples from 201 CRCs and 31 non-CRCs revealed the N₁,N12-diacetylspermine showing the highest area under the receiver operating characteristic curve (AUC), 0.794 (the 95% confidence interval (CI): 0.704-0.885, p < 0.0001), to differentiate CRC from the benign and healthy controls. Overall, 59 samples were analyzed to evaluate the reproducibility of quantified concentrations, acquired by collecting three times on three days each from each healthy control. We confirmed the stability of the observed quantified values. A machine learning method using combinations of polyamines showed a higher AUC value of 0.961 (95% CI: 0.937-0.984, p < 0.0001). Computational validations confirmed the generalization ability of the models. Taken together, polyamines and a machine-learning method showed potential as a screening tool of CRC. colorectal cancer; liquid chromatography-mass spectrometry; machine learning; polyamine; urine
41. BACKGROUND: Prophylactic cranial irradiation (PCI) is recommended for patients with limited-disease small-cell lung cancer (LD-SCLC) who achieved good response to definitive chemoradiotherapy. Pubmed BACKGROUND: Prophylactic cranial irradiation (PCI) is recommended for patients with limited-disease small-cell lung cancer (LD-SCLC) who achieved good response to definitive chemoradiotherapy. However, most clinical studies lacked brain imaging scans before PCI. Our study aimed to investigate whether PCI has a survival benefit in patients who have no brain metastases (BM) confirmed via magnetic resonance imaging (MRI) before PCI. RESULTS: Eighty patients were included in this study. Sixty patients received PCI (PCI group) and 20 patients did not (non-PCI group). OS was not significantly different between the two groups. The median OS time was 4.3 years (95% CI: 2.6 years-8.6 years) in the PCI group and was not reached (NR) (95% CI: 1.9 years-NR) in the non-PCI group (p = 0.542). Moreover, no differences were observed in the 3-year rates of PFS (46.2% and 44.4%, p = 0.720) and cumulative incidence of BM (24.0% vs. 27%, p = 0.404). CONCLUSIONS: Our result suggests that PCI may not have a survival benefit in patients with LD-SCLC confirmed to have no BM after initial therapy, even if patients achieve a good response to definitive chemoradiotherapy. PATIENTS AND METHODS: We retrospectively evaluated patients with LD-SCLC who were confirmed to have no BM via MRI after initial chemoradiotherapy at the Shizuoka Cancer Center between September 2002 and August 2015. The overall survival (OS), progression-free survival (PFS), and cumulative incidence of BM were estimated using the Kaplan-Meier method between patients who received PCI and those who did not. Propensity score matching was used to balance baseline characteristics. brain metastases; limited disease; prophylactic cranial irradiation; small-cell lung cancer
42. Neuroendocrine tumors of the pancreas (pNETs) are a rare group of neoplasms that originate from the endocrine portion of the pancreas. Pubmed Neuroendocrine tumors of the pancreas (pNETs) are a rare group of neoplasms that originate from the endocrine portion of the pancreas. Tumors that either secrete or do not secrete compounds, resulting in symptoms, can be classified as functioning and non-functioning pNETs, respectively. The prevalence of such tumors has recently increased due to the use of more sensitive imaging techniques, such as multidetector computed tomography, magnetic resonance imaging and endoscopic ultrasound. The biological behavior of pNETs varies widely from indolent, well-differentiated tumors to those that are far more aggressive. The most effective and radical treatment for pNETs is surgical resection. Over the last decade, minimally invasive surgery has been increasingly used in pancreatectomy, with laparoscopic pancreatic surgery (LPS) emerging as an alternative to open pancreatic surgery (OPS) in patients with pNETs. Non-comparative studies have shown that LPS is safe and effective. In well-selected groups of patients with pancreatic lesions, LPS was found to results in good perioperative outcomes, including reduced intraoperative blood loss, postoperative pain, time to recovery, and length of hospital stay. Despite the encouraging results of studies from highly specialized centers with extensive experience, no randomized trials to date have conclusively validated these findings. Indications for minimally invasive LPS for patients with pNETs remain unclear. This review presents the current state of LPS for pNETs. Neuroendocrine tumor of the pancreas (pNETs); laparoscopic pancreatic surgery (LPS); minimally invasive surgery
43. A 0. Pubmed A 0.5%-iron-containing fiducial marker, Gold AnchorTM (Naslund Medical AB, Huddinge, Sweden), has been recently developed. Herein, we report our initial experiences with the clinical use of the Gold AnchorTM (GA) in radiotherapy for liver tumors. Data of four consecutive patients with liver tumors, including two liver metastases and two hepatocellular carcinomas, were retrospectively analyzed. The GA was percutaneously placed under local anesthesia, close to the tumor. Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (MRI) was performed after the placement of the GA. Radiotherapy was designed using the volumetric modulated arc therapy technique. All procedures for placement of the GA were successfully performed with no complications. The GA exhibited various forms in the liver in the four patients. All of the GAs were well-detected on MRI, planned computed tomography (CT), and cone-beam CT. Additionally, the tadpole-like shape of the GA showed better detectability than the uptake of lipiodol emulsion and could be used for three-dimensional correlation during setup in daily image-guided radiotherapy. GA was a useful tool in image registration of radiotherapy with a high applicability. Additionally, the tadpole-like shape can be recommended for liver radiotherapy. Our findings suggest that the GA will indeed be useful in clinical practice. fiducial marker; hepatocellular carcinoma; image guided radiation therapy; intensity modulated radiotherapy; liver metastasis; stereotactic ablative radiation therapy; stereotactic body radiation therapy

3D Tissue Models
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.